IMM Immutep

Immutep's stock surged after it released a market-sensitive update showing positive mature clinical data from its INSIGHT-003 trial and a TACTI-004 progress report, signalling encouraging results for its cancer immunotherapy pipeline.

The stock likely fell ahead of a positive clinical data announcement, possibly due to profit-taking or positioning before the release.

Insufficient evidence to determine the cause of the price move; the only news article is a broad market update unrelated to IMMUTEP.

Immutep's Q3 FY26 Quarterly Activities Report likely disappointed investors, triggering a sell-off.

Immutep shares fell 11.27% on April 28, 2026, likely due to a negative market reaction to its Q3 FY26 quarterly activities report released on April 30, 2026, which may have contained disappointing operational updates or financial results.

Acceptance of an abstract on Efti for presentation at ASCO 2026 likely drove the price up.

A massive post-FDA-news rally over the previous two days likely triggered profit-taking, causing an -8% pullback on high volume.

FDA granted Orphan Drug Designation for Immutep's cancer therapy and Phase 2 trial success, triggering a massive share price surge.

The abnormal 10% decline on 2026-04-13 likely reflects profit-taking or a market reaction preceding the subsequent surge, but specific negative news for that date is absent; the most plausible driver is sector flow or a broad market downturn.

Immutep discontinued its lung cancer drug trial, causing a 16.39% drop.

Immutep's stock surged 35.56% on March 15, 2026, likely as a rebound after a massive crash earlier that week, possibly driven by bargain hunting and attractively valued pipeline prospects.

Immutep's stock crashed after discontinuing its TACTI-004 Phase III trial for lung cancer due to futility.